drugset
drugset / Trial / NCT02235688

Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors

NCT02235688 ↗

Phase 1 Completed 30 enrolled ImmunityBio, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 1 study to investigate the safety and activity of aldoxorubicin plus gemcitabine in Subjects with solid tumors.

Timeline

Start
2014-08
Primary completion
2017-01
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Aldoxorubicin Small molecule 170 mg/m2 Intravenous
Subject Aldoxorubicin Small molecule 250 mg/m2 Intravenous
Subject Aldoxorubicin Small molecule 350 mg/m2 Intravenous
Subject Gemcitabine Small molecule 900 mg/m2 —

Indications

metastatic neoplasm